🧬 S-23 Research Overview

Experimental SARM and Androgen-Receptor Research Compound

S-23 is an experimental, nonsteroidal selective androgen-receptor modulator commonly classified as a SARM. It was investigated primarily as a potential component of a reversible male hormonal-contraception system.

Preclinical research characterized S-23 as a potent androgen-receptor agonist with measurable activity in muscle, bone, reproductive tissue, and endocrine signaling.

Research has examined S-23 in connection with:

• Androgen-receptor binding

• Lean-tissue growth

• Bone-related activity

• Gonadotropin suppression

• Testosterone suppression

• Spermatogenesis

• Reproductive recovery following discontinued exposure

S-23 has not been approved by the FDA for human or veterinary use.

⚙️ How S-23 Is Being Studied

S-23 binds to androgen receptors, which regulate biological processes involving skeletal muscle, bone, reproductive function, and secondary sex characteristics.

Unlike testosterone, S-23 is nonsteroidal and cannot be directly converted into estrogen or dihydrotestosterone through the same metabolic pathways. That does not mean its effects are limited exclusively to muscle and bone or that it avoids androgen-related risks.

In the principal preclinical investigation of S-23, researchers reported high androgen-receptor binding affinity and oral activity in animal models.

Research interest: androgen-receptor selectivity, anabolic activity, reproductive suppression, skeletal-muscle biology, bone maintenance, and hormonal contraception.

🔬 Anabolic and Androgenic Activity

Animal experiments reported changes in androgen-responsive tissues following S-23 exposure.

In castrated-rat models, S-23 produced dose-related anabolic activity involving muscle tissue. The researchers also observed effects in androgen-sensitive reproductive tissues, demonstrating that the compound was not exclusively active in skeletal muscle.

These findings established S-23 as a biologically potent androgen-receptor modulator. However, changes in rat muscle weight do not demonstrate improved strength, body composition, recovery, or athletic performance in humans.

Claims that S-23 is stronger than every other SARM are also difficult to substantiate because binding affinity, animal-tissue activity, and real-world clinical outcomes are different measurements.

🧪 Hormonal-Contraception Research

The most distinctive research involving S-23 concerned male hormonal contraception.

In male rats, S-23 was investigated alongside estradiol benzoate. The combination suppressed luteinizing hormone, follicle-stimulating hormone, testosterone, and sperm production under the experimental conditions.

During mating trials, infertility was achieved in the treated animals. Following discontinued exposure, sperm production and fertility gradually recovered in the studied rats.

These results made S-23 scientifically notable as a possible component of a reversible hormonal-contraception strategy. They do not establish that hormonal or reproductive recovery would occur predictably in humans.

💪 Skeletal-Muscle Research

S-23 has gained attention because androgen-receptor activation can influence muscle protein metabolism and lean tissue.

Preclinical findings involving S-23 included:

• Increased weight of selected muscles

• Dose-dependent anabolic activity

• Maintenance of certain androgen-responsive tissues

• Biological activity following oral administration

These findings are sometimes promoted as proof of dramatic muscle growth, strength enhancement, or muscle preservation during calorie restriction. Those outcomes have not been established in controlled human trials.

There is also insufficient evidence to claim that S-23 specifically reduces fat mass or increases basal metabolic rate in humans.

🦴 Bone-Related Research

Androgen receptors participate in bone growth and maintenance, which has made bone biology an important area of general SARM research.

Preclinical experiments involving S-23 reported activity relevant to androgen-responsive bone and muscle pathways. However, there are no controlled clinical trials establishing that S-23 improves bone density, prevents fractures, or safely treats osteoporosis.

General findings involving other SARMs should not automatically be attributed to S-23.

🔬 Why S-23 Is Scientifically Distinctive

S-23 remains a notable experimental SARM because it combines several measurable properties:

• High receptor affinity: demonstrated strong binding to the androgen receptor

• Oral activity: produced biological effects following oral administration in animals

• Anabolic signaling: increased selected muscle measurements in preclinical models

• Endocrine suppression: substantially affected gonadotropins and testosterone

• Reproductive effects: suppressed spermatogenesis and fertility in male rats

• Recovery research: reproductive function returned after exposure ended in the animal model

This profile makes S-23 particularly useful for investigating the relationship between androgen-receptor activity, tissue selectivity, and reproductive suppression.

⚠️ Major Research Limitations

The evidence for S-23 is overwhelmingly preclinical. No completed controlled human trials have established its safety, effectiveness, pharmacokinetics, or appropriate exposure range.

Important limitations include:

• Human anabolic or fat-loss benefits have not been established.

• Testosterone, LH, and FSH suppression are central pharmacological effects—not minor side effects.

• Animal reproductive recovery does not guarantee human recovery.

• Human liver, cardiovascular, psychiatric, fertility, and prostate risks remain inadequately characterized.

• Claims involving aggression, “dry gains,” or rapid strength increases are primarily anecdotal.

• No validated human dosage, cycle length, or post-exposure protocol exists.

• Research-material purity, identity, concentration, and stability may vary.

• S-23 is prohibited in competitive sport.

• It has no FDA-approved medical indication.

⭐ Evidence-Based Verdict

S-23 is a potent experimental androgen-receptor modulator with compelling preclinical findings involving anabolic activity, endocrine suppression, and reversible infertility in male rats.

Its hormonal-contraception research makes it scientifically distinctive among experimental SARMs. At the same time, its pronounced effects on testosterone, gonadotropins, and spermatogenesis demonstrate that it is not a mild or minimally suppressive compound.

The most accurate conclusion is that S-23 is a powerful laboratory research tool with substantial biological activity, no established human performance benefits, and an incompletely characterized safety profile.

Explore S-23 research materials

Affiliate disclosure: The link above is a referral link. I may receive a commission if it is used, at no additional cost to the purchaser.

For laboratory-research purposes only. Not for human or veterinary use.

This content is provided solely for general educational discussion of scientific research. It does not provide dosing, cycle, stacking, post-cycle, or administration guidance; does not encourage self-experimentation; and does not claim that S-23 can diagnose, treat, cure, or prevent any disease.